Pharmacogenetic Information on Drug Labels of the Italian Agency of Medicines (AIFA): Actionability and Comparison Across Other Regulatory Agencies

• Published in: Clinical and translational science Vol. 18; no. 2; pp. e70138 - n/a
• Main Authors: Moschella, Antonino, Mourou, Soumaya, Perfler, Samantha, Zoroddu, Enrico, Bezzini, Daiana, Soru, Dorian, Trignano, Claudia, Miozzo, Monica, Squassina, Alessio, Cecchin, Erika, Floris, Matteo
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.02.2025; John Wiley and Sons Inc; Wiley
• Subjects: Agreements; AIFA; Biomarkers; Classification; Clinical medicine; Comparative analysis; Discordance; Drug Approval; Drug Labeling - legislation & jurisprudence; Drug Labeling - standards; drug labels; Drugs; FDA approval; Genes; Government Agencies; Humans; Hyperthermia; Immunomodulation; Italy; Kappa coefficient; level of actionability; Marketing; pharmacogenetic testing; Pharmacogenetics - legislation & jurisprudence; Pharmacogenomic Testing - legislation & jurisprudence; Pharmacogenomic Testing - standards; Pharmacogenomics; Regulatory agencies; Side effects; United States Food and Drug Administration; Italy; AIFA; drug labels; level of actionability; pharmacogenetic testing
• ISSN: 1752-8054; 1752-8062; 1752-8062
• DOI: 10.1111/cts.70138

ABSTRACT To plan future steps for the implementation and regulation of pharmacogenetic testing, any issue in the management of pharmacogenetic information by regulatory bodies must be identified. In this paper, an analysis of pharmacogenetic information in the summary of product characteristics (SmCPs) of drugs approved by Italian Drug Agency (AIFA) was conducted. Among 4214 SmCPs of 1063 active ingredients, 53.2% (n = 2240) included pharmacogenetic information in at least one section, most frequently for drugs in the Anatomical Therapeutic Chemical category “Antineoplastic and immunomodulatory agents”. To contextualize these data in the international scenario, a pharmacogenetic level of actionability, based on AIFA SmCPs, was assigned to 608 drug/gene pairs included in FDA's “Table of Pharmacogenomic Biomarkers in Drug Labels”, according to PharmGKB (The Pharmacogenomics Knowledge Base). Approximately 67% of drug/gene pairs were deemed classifiable: Based on SmCPs phrasing, for half of them the genetic testing was cataloged as “required” or “recommended” (mainly tumor somatic variants), whereas 40% as “actionable” (mostly PK/PD‐related germline variants). The comparison with other regulatory agencies highlighted a discordance in the assigned pharmacogenetic levels of actionability ranging from 1% to 14%. This discrepancy may also point out the need to rethink the language used in AIFA‐approved SmCPs to clarify whether a pharmacogenetic test is necessary or not and for which subjects it has been recommended. For the first time, a detailed evaluation and comparative analysis of the pharmacogenetic information on Italian SmCPs was presented, placing it in an international context and laying the groundwork for rethinking pharmacogenetic indications in AIFA‐approved SmCPs.